Omega Funds leads $35M Series A to fuel Attenua's cough program, set for proof-of-concept this year
As Attenua continues to develop its lead program for chronic cough, it will be doing so with $35 million in the bank and under the leadership of a new CEO.
In conjunction with the Series A funding — led by Omega Funds with participation from a syndicate that includes Abingworth, OrbiMed and Redmile Group — Michael Kitt has taken the helm from founder Jing Liang. Kitt had previously served as CMO at a few biotechs, most recently at another cough drug developer, Afferent Pharmaceuticals, prior to its acquisition by Merck.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.